Hematologic responses in patients with aplastic anemia treated with deferasirox: A post hoc analysis from the EPIC study

Haematologica

Volumn 98, Issue 7, 2013, Pages 1045-1048

  Lee, Jong Wook ^a   Yoon, Sung Soo ^b   Shen, Zhi Xiang ^c   Ganser, Arnold ^d   Hsu, Hui Chi ^e   El Ali, Ali ^f   Habr, Dany ^f   Martin, Nicolas ^f   Porter, John B ^g  

^a The Catholic University of Korea   (South Korea)

^b Seoul National University   (South Korea)

^c SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^f NOVARTIS PHARMA AG   (Switzerland)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERASIROX;

ADOLESCENT; ADULT; AGED; APLASTIC ANEMIA; ARTICLE; BLOOD TRANSFUSION; CHILD; FEMALE; FERRITIN BLOOD LEVEL; HEMATOLOGICAL PARAMETERS; HEMATOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IRON CHELATION; IRON OVERLOAD; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; POST HOC ANALYSIS; RETICULOCYTE COUNT; SCHOOL CHILD; THROMBOCYTE COUNT;

ADOLESCENT; ADULT; ANEMIA, APLASTIC; BENZOATES; BLOOD PLATELETS; CHILD; FEMALE; FERRITINS; HEMOGLOBINS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IRON CHELATING AGENTS; MALE; MIDDLE AGED; NEUTROPHILS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TRIAZOLES; YOUNG ADULT;

EID: 84879597351     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.077669     Document Type: Article

References (23)

1. Marsh JC, Ball SE, Cavenagh J, Darbyshire P, Dokal I, Gordon-Smith EC, et al. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol. 2009;147(1):43-70
2. AlKhouri N, Ericson SG. Aplastic anemia: review of etiology and treatment. Hosp Physician. 1999;35:46-52
3. Lee JW. Iron chelation therapy in the myelodysplastic syndromes and aplastic anemia: a review of experience in South Korea. Int J Hematol. 2008;88(1):16-23
4. Lee J-W, Yoon S-S, Shen ZX, Ganser A, Hsu H-C, Habr D, et al. Iron chelation therapy with deferasirox in patients with aplastic anemia: A subgroup analysis of 116 patients from the EPIC trial. Blood. 2010; 116(14):2448-2454
5. Min Y, Cheong J, Kim H, Lee K, Yoon S, Lee J, et al. A multi-center, open label study evaluating the efficacy of iron chelation therapy with deferasirox in transfusional iron overload patients with myelodysplastic syndromes or aplastic anemia using quantitative R2 MRI. Leuk Res. 2009;33(1 Suppl):S118-S119 (Abstract P102).
6. Porter J, Galanello R, Saglio G, Neufeld EJ, Vichinsky E, Cappellini MD, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol. 2008; 80(2):168-176
7. Park SJ, Han CW. Complete hematopoietic recovery after continuous iron chelation therapy in a patient with severe aplastic anemia with secondary hemochromatosis. J Korean Med Sci. 2008;23(2):320-323
8. Oliva EN, Ronco F, Marino A, Alati C, Pratico G, Nobile F. Iron chelation therapy associated with improvement of hematopoiesis in transfusion-dependent patients. Transfusion. 2010;50(7):1568-1570
9. Koh KN, Park M, Kim BE, Im HJ, Seo JJ. Restoration of hematopoiesis after iron chelation therapy with deferasirox in 2 children with severe aplastic anemia. J Pediatr Hematol Oncol. 2010;32(8):611-614
10. Lee JW, Jang PS, Chung NG, Cho B, Jeong DC, Kim HK. Iron chelation therapy with deferasirox results in recovery of hematopoiesis in a child with aplastic anemia. Pediatr Hematol Oncol. 2011;28(8): 718-720
11. Hartmann J, Sinzig U, Wulf G, Truemper LH, Braulke F, Konietschke F, et al. Evidence for a suppression of the colony forming capacity of erythroid progenitors by iron overload in patients with MDS. Blood. 2008;112(11): (Abstract 2694).
12. Guariglia R, Martorelli MC, Villani O, Pietrantuono G, Mansueto G, D'Auria F, et al. Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: A brief review. Leuk Res. 2011;35 (5):566-570
13. Cappellini MD, Porter JB, El-Beshlawy A, Li C-K, Seymour JF, Elalfy M, et al. Tailoring iron chelation by iron intake and serum ferritin trends: the prospective multicenter EPIC study of deferasirox in 1744 patients with various transfusion-dependent anemias. Haematologica. 2010;95(4):557-566
14. Camitta BM. What is the definition of cure for aplastic anemia? Acta Haematol. 2000; 103(1):16-18
15. Capalbo S, Spinosa G, Franzese MG, Palumbo G. Early deferasirox treatment in a patient with myelodysplastic syndrome results in a long-term reduction in transfusion requirements. Acta Haematol. 2009; 121(1):19-20
16. Jensen PD, Heickendorff L, Pedersen B, Bendix-Hansen K, Jensen FT, Christensen T, et al. The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol. 1996; 94(2):288-299
17. Messa E, Cilloni D, Messa F, Arruga F, Roetto A, Saglio G. Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis. Acta Haematol. 2008;120(2):70-74
18. Breccia M, Loglisci G, Salaroli A, Cannella L, Santopietro M, Alimena G. Deferasirox treatment interruption in a transfusionrequiring myelodysplastic patient led to loss of erythroid response. Acta Haematol. 2010;124(1):46-48
19. Okabe H, Suzuki T, Omori T, Mori M, Uehara E, Hatano K, et al. Hematopoietic recovery after administration of deferasirox for transfusional iron overload in a case of myelodysplastic syndrome. Rinsho Ketsueki. 2009;50(11):1626-1629
20. Gattermann N, Finelli C, Della Porta M, Fenaux P, Stadler M, Guerci-Bresler A, et al. Hematologic responses with deferasirox therapy in transfusion-dependent myelodysplastic syndromes patients. Haematologica. 2012;97(9):1364-1371
21. List AF, Baer MR, Steensma DP, Raza A, Esposito J, Martinez-Lopez N, et al. Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome. J Clin Oncol. 2012;30(17):2134-2139
22. Vreugdenhil G, Smeets M, Feelders RA, van Eijk HG. Iron chelators may enhance erythropoiesis by increasing iron delivery to haematopoietic tissue and erythropoietin response in iron-loading anaemia. Acta Haematol. 1993;89(2):57-60
23. Gattermann N, Rachmilewitz EA. Iron overload in MDS-pathophysiology, diagnosis, and complications. Ann Hematol. 2011; 90(1):1-10.